FFO
ESPR

Fortitude Family Office’s Esperion Therapeutics ESPR Stock Holding History

Fortitude Family Office’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$768 Hold
243
– – ﹤0.01% 1846
2026
Q1 		$666 Buy
+243
New +$769 ﹤0.01% 1622

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Fortitude Family Office's ESPR Position: Q2 2026 in Review

Fortitude Family Office held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 243 shares worth $768. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

Fortitude Family Office first reported a position in ESPR in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Fortitude Family Office held 243 shares of Esperion Therapeutics worth $768 as of Q2 2026.
  • Fortitude Family Office left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1846 holding.
  • Fortitude Family Office first reported a position in Esperion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.